We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Factory Location: 2 Zhangshan Road, RenHe Industrial Park, Hangzhou, Zhejiang China
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: yes
Payment Terms: T/T
English name
Adenosine Ar
English aliases
AR; Adenosine free base
CAS No.
58-61-7
EINECS No.
200-389-9
Molecular formula
C10H13N5O4
Molecular weight
267.25
Structural formula
Purity(HPLC)
≥99%
Usage
1, Adenosine is a vasodilator and also can be used as antiarrhythmic drug.The main indications include:
(1) Paroxysmal supraventricular tachycardia. For the treatment of paroxysmal supraventricular tachycardia participation in the atrioventricular node reentry ,Adenosine is very effective as a drug of choice for treatment. Because of its short half-life and insignificant side effects, it can also be used when verapamil is ineffective or contraindicated.
(2) Differential diagnosis of ventricular tachycardia.
(3) Adjuvant of thallium-201 myocardial perfusion imaging.
2, Adenosine is used for the synthesis of adenosine triphosphate (ATP), Adenosine 5'-monophosphate(AMP), Vidarabine, coenzyme A and other important intermediates.
3, Adenosine can stimulate hair growth to reduce hair loss.
Packing size
25kg/barrel
Storage
Keep dry and away from light and stored in ventilated cool library.
Audited Supplier
Pharma Sources Insight JANUARY 2024
